Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BASF subsidiary Metanomics Health launches MetaMap®Tox

Published: Monday, August 13, 2012
Last Updated: Monday, August 13, 2012
Bookmark and Share
MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling customers to better and faster identify potential safety risks of test compounds in in vivo studies of rats. Developed in-house by BASF’s Experimental Toxicology and Ecology unit and marketed through Metanomics Health, MetaMap®Tox addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology mechanism and the ability for translation to clinical use.

In the development of novel drugs, early recognition of potential toxicological effects and their underlying mechanisms is of utmost importance. To support the cost- and time-effective development of new compounds with more favorable toxicological profiles, Metanomics Health GmbH is launching MetaMap®Tox, a powerful tool for biopharmaceutical safety research. MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling customers to better and faster identify potential safety risks of test compounds in in vivo studies of rats.


MetaMap®Tox has been developed in-house by BASF’s Experimental Toxicology and Ecology unit and will be marketed through Metanomics Health. Over a period of seven years, more than 500 chemical entities were thoroughly tested in vivo to generate and validate more than 100 metabolomic fingerprints of different toxicological modes of action. These data allow for a faster and better assessment of toxicological profiles of new chemical entities (NCEs). MetaMap®Tox thereby addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology mechanism and the ability for translation to clinical use.

MetaMap®Tox has been technically validated by the Drug Safety Executive Council (DSEC), in a consortium approach of twelve leading biopharmaceutical companies following the goal to advance new technologies for the development of better and safer medicines worldwide. It will be offered in two distinct service packages: MetaMap®Tox Screener and MetaMap®Tox Profiler.

MetaMap®Tox Screener enables lead optimization in exploratory non-GLP (Good Laboratory Practice) tox programs based on predictive metabolomic patterns in rat plasma in 14-day studies. Benefits include coverage of systemic toxicological profiles of NCEs and unique mechanistic understanding based on 25 specific & predictive toxicological modes of action (MoA) in 11 different target organs.

MetaMap®Tox Profiler is targeting early safety assessment in a preclinical GLP toxicology setting. MetaMap®Tox Profiler covers 46 validated toxicological modes of action (MoA) in a total of 17 different target organs. Key attributes comprise the potential to detect drug side effects (e.g. liver and thyroid injury) at an early stage and a detailed understanding of systemic toxicology of NCEs, both leading to an improved lead selection and guidance for further toxicological tests.

"We are very happy to launch MetaMap®Tox Screener and MetaMap®Tox Profiler," said Tim Boelke, Managing Director of Metanomics Health. "These have been designed based on feedback by the DSEC, whose members confirmed their great interest in a tool that provides predictive toxicological assessments already in the exploratory non-GLP phase. We are convinced that MetaMap®Tox addresses this key unmet need."

"MetaMap®Tox has been developed by an interdisciplinary BASF team over a period of more than seven years to obtain early information on the toxicological profile whilst reducing the number of animals used," said Bennard van Ravenzwaay, Senior Vice President, Experimental Toxicology and Ecology at BASF. "MetaMap®Tox is already in routine use at BASF, contributing to faster decision making and significant savings in terms of cost and time to market for the BASF Group."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Genes That Increase Children's Risk Of Blood Infection Identified
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children.
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!